Histiocytic and dendritic cell neoplasm
MONDO:0006247Rare tumors that affect the hematopoietic and lymphoid tissues. The cells of origin are the histiocytes and accessory cells. They can occur at any age and show no significant variations in geographical distribution. This category includes the histiocytic sarcoma, Langerhans cell histiocytosis, Langerhans cell sarcoma, interdigitading dendritic cell sarcoma/tumor, follicular dendritic cell sarcoma/tumor, and dendritic cell sarcoma, not otherwise specified. (WHO, 2001)
Also known as: histiocytic and Dendritic cell neoplasms, histiocytic and Dendritic cell tumors, histiocytic and Dendritic cell tumours, histiocytic and dendritic cell neoplasm, histiocytic and dendritic cell, histiocytic and dendritic cell cancer, histiocytic and dendritic cell tumor, histiocytic and dendritic cell tumour
1935 clinical trials for this condition and its sub-types, 10 tagged with Histiocytic and dendritic cell neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Histiocytic and dendritic cell neoplasm
-
Dendritic cell tumor 0 trials · 92 incl. sub-types
3 sub-types
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- Langerhans cell histiocytosis 40 trials · 41 incl. sub-types Sub-types →
- Reticulum cell sarcoma 0 trials
-
Histiocytic sarcoma 9 trials
Most studied deeper sub-types
-
New hope for kids with tough cancers: targeted drug attacks gene flaw
Disease control OngoingThis study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC